Synaptic Pharmaceutical Corporation

Bayer Pharmaceuticals Corporation

Other

Merck + Co., Inc.

Novartis Ag

H. Lunbeck A/s

H. Lundbick A/s

Wai C Wong

Charles Gluchowski

Dhanapalan Nagarathnam

Mohammad R Marzabadi

George Chiu

Stewart Alwyn Noble

Yoon T Jeon

Bharat Lagu

T G Murali Dhar

John M Wetzel

Shou Wu Miao

Mohammed R Marzabadi

Michael A Patane

Yasuchika Yamaguchi

T G Dhar

Roger Astbury Smith

Stephen J O'Connor

Soongyu Choi

Mark G Bock

Harold C Kluender

Gan Wang

Walter Schilling

Zhonghua Zhang

Jianmei Fan

Ning Miao Su

Harold C E Kluender

Rico C Lavoie

Stephan-Nicholas Wirtz

Furahi Achebe

Shihong Ying

Brent L Podlogar

Manesh N Desai

Heinrich R&uuml;eger

Peter B&uuml;hlmayer

Tg Murali Dhar

This invention is directed to bicyclic and tricyclic compounds which are selective antagonists for NPY (Y5) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of this invention and a pharmaceutically acceptable carrier. The invention provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides the use of a compound of the invention for the preparation of a pharmaceutical composition for treating an abnormality, wherein the abnormality is alleviated by decreasing the activity of a human Y5 receptor.

Selective NPY (Y5) antagonists

This invention relates to 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives which have been found to suppress appetite and induce weight loss. The invention also provides methods for synthesis of the compounds, pharmaceutical compositions comprising the compounds, and methods of using such compositions for inducing weight loss and treating obesity and obesity-related disorders.

Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity

This invention is directed to triazine derivatives, bicyclic compounds and tricyclic compounds which are selective antagonists for a NPY (Y5) receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of this invention and a pharmaceutically acceptable carrier. This invention provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The invention further provides the use of a compound of the invention for the preparation of a pharmaceutical composition for treating an abnormality, wherein the abnormality is alleviated by decreasing the activity of a human Y5 receptor.

This invention relates to substituted imidazole derivatives which have been found to suppress appetite and induce weight loss. The invention also provides methods for synthesis of the compounds, pharmaceutical compositions comprising the compounds, and methods of using such compositions for inducing weight loss and treating obesity and obesity-related disorders.

Preparation and use of imidazole derivatives for treatment of obesity

This invention is directed to novel imidazole and imidazoline derivatives which are selective agonists for cloned human &agr; adrenergic receptors. This invention is also related to the use of these compounds for the treatment of any disease where modulation of the &agr; receptors may be useful. The invention further provides for a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

Imidazole and imidazoline derivatives and uses thereof

5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines

This invention is directed to oxazolidinone compounds which are selective antagonists for human &agr; receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia and for the treatment of any disease where the antagonism of the &agr; receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

Oxazolidinones and uses thereof

This invention provides dihydropyridines useful for treatment of prostatic hyperplasia, inhibition of cholesterol synthesis, and/or reduction of intraocular pressure.

Dihydropyridines and new uses thereof

The invention provides a method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound having the structure:

This invention is directed to novel imidazole and imidazoline derivatives which are selective agonists for cloned human &agr;,adrenergic receptors. This invention is also related to the use of these compounds for the treatment of any disease where modulation of the &agr;,receptors may be useful. The invention further provides for a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

Imidazoline derivatives and uses thereof

This invention is directed to dihydropyrimidine compounds of the following formula:

This invention is directed to the use of dihydropyrimidine compounds, which are selective antagonists for cloned human &agr;,receptors, for the treatment of benign prostatic hyperplasia and other diseases where antagonism of the human &agr;,receptor is useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-identified compounds and a pharmaceutically acceptable carrier.

This invention is directed to dihydropyrimidine compounds which are selective antagonists for human &agr;,receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia and for the treatment of any disease where the antagonism of the &agr;,receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

Dihydropyrimidines and uses thereof

This invention is directed to tricyclic compounds which are selective antagonists for NPY (Y5) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.

Selective NPY (Y5) antagonists (tricyclics)

Growing community of inventors

Hamden, CT, United States of America

Wai C Wong